Aestus Pharmaceuticals India Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
as on 28-05-2024
- Paid Up Capital ₹ 0.50 M
as on 28-05-2024
- Company Age 19 Year, 5 Months
- Last Filing with ROC 31 Mar 2023
About Aestus Pharmaceuticals India
The Company is engaged in the Chemicals Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.50 M, as per Ministry of Corporate Affairs (MCA) records.
Amanjot Chawla, Inderjit Kaur, and Iqbal Singh serve as directors at the Company.
- CIN/LLPIN
U24232CH2005PLC043164
- Company No.
138080
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
28 Jun 2005
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Chandigarh
Industry
Company Details
- Location
South West Delhi, Delhi, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Aestus Pharmaceuticals India?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Iqbal Singh  | Managing Director | 01-Aug-2014 | Current |
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Amanjot Chawla | Director | 01-Aug-2014 | Current |
| Inderjit Kaur | Director | 01-Aug-2014 | Current |
Financial Performance and Corporate Structure Insights of Aestus Pharmaceuticals India.
Aestus Pharmaceuticals India Limited, for the financial year ended 2017, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Aestus Pharmaceuticals India?
In 2017, Aestus Pharmaceuticals India had a public holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Innovative Financial Management Private LimitedActive 15 years 1 monthAmanjot Chawla, Inderjit Kaur and 1 more are mutual person
Ifmsecurities Private LimitedActive 1 year 11 monthsAmanjot Chawla, Inderjit Kaur and 1 more are mutual person
- Peak Vision Fund Private LimitedActive 10 months 14 days
Amanjot Chawla and Iqbal Singh are mutual person
- Read Rock Reality Private LimitedActive 2 years 6 months
Amanjot Chawla and Iqbal Singh are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Aestus Pharmaceuticals India?
Unlock and access historical data on people associated with Aestus Pharmaceuticals India, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Aestus Pharmaceuticals India, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Aestus Pharmaceuticals India's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
